OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Lymphatic propagation of α-synuclein	439
Microglia, spreaders of Aβ seeds	389
Transmembrane protein interacts with α-synuclein to confer risk of PD	338
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	261
Ventricular enlargement caused by aducanumab	252
Getting specific: targeting Fc receptors in myasthenia gravis	230
Brain stimulation aids walking after spinal injury	229
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	225
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	211
Global synergistic actions to improve brain health for human development	197
Diagnosis and management of migraine in ten steps	184
Refining oxytocin therapy for autism: context is key	179
Neural cell state shifts and fate loss in ageing and age-related diseases	175
NODDI reveals brain microstructural changes in multiple sclerosis	172
Disease-specific modifications of tau protein	169
Continuous levodopa production by an artificial enzyme	168
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	167
The impact of rare genetic variants on Alzheimer disease	166
Spinal muscular atrophy treatment in utero	151
The role of the gut microbiota in multiple sclerosis	150
Mitochondrial DNA instability in Huntington disease	149
Study reveals new ALS risk genes	127
Microglia subset associated with high-grade glioma	125
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	121
Is post-stroke cognitive impairment all about real estate?	118

The Digitized Memory Clinic	114
TREM2 mediates phagocytosis in glioblastoma	111
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	111
Imperatives and co-benefits of research into climate change and neurological disease	111
Amyloid-β: a potential link between epilepsy and cognitive decline	105
Ultrasound lets gene therapy into the brain	103
Brain volume is associated with cognition in MS	101
Role for endogenous retrovirus in FTD	100
Menopause influences tau pathology	99
Amyloid plaques: hotspots for microglial turnover	98
Neurological care for LGBT+ people	98
Management of freezing of gait — mechanism-based practical recommendations	97
Psychosis-causing lesions mapped to a hippocampal circuit	94
α-Synuclein pathology as a target in neurodegenerative diseases	93
Neuroinflammation predicts cognitive decline in FTD	89
The challenges of anti-tau therapeutics in Alzheimer disease	89
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	84
Racial differences in the response to multiple sclerosis therapy	83
Gene therapy effective in model of infantile parkinsonism	83
MRI-based deep learning for TLE diagnosis	82
Diversity, equity and inclusion in neurology	80
Brain imaging illuminates cognitive impairment in multiple sclerosis	79
APOE ε4 influences Parkinson disease progression	78
Precision neuroimmunology in multiple sclerosis — the horizon is near	72
Author Correction: Viral pathogens increase risk of neurodegenerative disease	72
First trials test targeting of α-synuclein for Parkinson disease	67
Parkinson disease pathology can originate in the kidney	65
Gene therapy for seizures in focal cortical dysplasia	65
New IDEAS about amyloid, race and dementia disparities	64
Evidence for altered astrocyte function in Duchenne muscular dystrophy	64
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	64
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	63
Food is brain medicine — relevance and translation to neurology	62
Neurosteroids alleviate seizures in rats	61
Glymphatic dysfunction in PD clinical progression	59
A new biological classification for Parkinson disease	58
Thalamic inflammation — a therapeutic target for brain injury?	58
Exosomal microRNA is promising biomarker in PD	57
Ultrasound ablation treatment for PD	55
Addressing disparities in neurology by building the workforce in LMICs	55
Spinal cord stimulation for the treatment of chronic pain	54
From the prodromal stage of multiple sclerosis to disease prevention	54
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	54
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	53
The role of glial cells in multiple sclerosis disease progression	51
Apparent changes in the epidemiology and severity of multiple sclerosis	50
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	49
The global and regional burden of diabetic peripheral neuropathy	49
Is Alzheimer disease a disease?	48
Synaptic degeneration in Alzheimer disease	46

Coeliac disease as a model for understanding multiple sclerosis	44
Hypothalamus loses control in migraine	43
Oligomeric tau could spread through synapses in AD	42
X-chromosome variants and PD in Latin America	41
Potassium channel openers — novel triggers of aura and migraine	40
Hypothyroidism is associated with dementia risk	40
The inter-relationship between delirium and dementia: the importance of delirium prevention	39
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	39
Neurofilament light chain induces neuroinflammation	39
Global epidemiology of migraine and its implications for public health and health policy	39
Cognitive impairment and World Trade Centre-related exposures	39
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	38
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	38
CAR T cells offer hope in glioblastoma	37
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	36
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	36
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	35
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	35
Moving towards meaningful patient and public engagement	35
Dual function of biomolecular condensates	35
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	35
Risk locus for paediatric astrocytoma identified	34
α-Synuclein seeds in amyotrophic lateral sclerosis	34
Change in stroke outcomes over 20 years	33
Prognostic plasma biomarkers for spinal cord injury	33
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	32
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	32
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	31
Huntington disease-like 2: insight into neurodegeneration from an African disease	31
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	31
New developments in guidelines for brain death/death by neurological criteria	31
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	30
Positron emission tomography in multiple sclerosis — straight to the target	30
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	28
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	28
Origins and immunopathogenesis of autoimmune central nervous system disorders	27
Twin study probes non-heritable immune aspects of multiple sclerosis	26
Deep learning distinguishes tauopathies	26
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	26
Multiple sclerosis treatment blunts SARS-CoV-2 antibody response	24
Neurogenesis altered in multiple neurodegenerative diseases	24
High rate of epilepsy in young individuals who died with COVID-19	22
Charting brain development across the human lifespan	21
Pathogenetic mechanisms and treatment targets in cerebral malaria	21
Serum NfL as an MS biomarker	20
ALS pathogenesis linked to actin barrier collapse	20
Genome-wide analysis furthers decoding of Alzheimer disease genetics	19
Aberrant protein networks in Alzheimer disease	19
The murky waters of sex differences in post-stroke cognitive impairment	18
Does antiherpetic antiviral therapy reduce the risk of dementia?	18
AI and protein structure and function in neurological disease: relevance to disease management	17
John Q. Trojanowski	17
BCAS1+ oligodendrocytes aid remyelination in MS	16
Pharmacological rehabilitation for stroke	16
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era	16
Author Correction: The complex aetiology of cerebral palsy	16
Molecular biomarkers for vascular cognitive impairment and dementia	15
Alzheimer disease in African American individuals: increased incidence or not enough data?	14
Neuroprognostication: a conceptual framework	14
Effects of diet on MS onset and course	13
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	13
Clocking the age of Parkinson disease onset	13
Nanoprobe for blood–brain barrier changes	13
Addressing disparities in the global epidemiology of stroke	13
Predictive tools in psychosis: what is ‘good enough’?	12
Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases	12
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	12
Altered muscle cholesterol transport in ALS	12
Nusinersen treatment response markers	12
Mechanistic insights into the interaction between epilepsy and sleep	12
Seizure-associated changes in the Golgi apparatus	11
Alzheimer disease seen through the lens of sex and gender	11
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	11
Multidimensional MRI detects astrogliosis	11
Sex and gender in neurodevelopmental conditions	11